Evidence of central nervous system toxicity was noted in two patients undergoing extradural analgmia for Caesarean section. There was no cardiovascular depression and both patients recovered rapidly. The patients had received total doses of bupivacaine plain solution of 357.5mg and 356.25 mg, respectively and the relationship of these to the clinical signs of bupivacaine toxicity is discussed.
Bupivacaine toxicity has been reported infrequently and the majority of cases have been the result of accidental and unsuspected intravascular injection. Some controversy exists regarding the relationship between neurological and cardiovascular toxicity: the hypoxia of the former may result in or add to the latter. Cardiovascular toxicity is quite refractory to treatment and requires prolonged resuscitation. We report two cases of bupivacaine toxicity after extradural analgesia during labour.
CASE REPORT

Casel
A primigravid patient, aged 22 yr and weighing 72.7kg, was admitted following the spontaneous onset of labour some 3 h previously. Two hours after admission, lumbar extradural analgesia was instituted, using 0.375% bupivacaine plain solution. Over the next 8h 30min, bupivacaine 69 ml was injected in divided doses, with good effect (total dose of 258.75 mg). At this point, the decision was made to deliver the patient by Caesarean section under extradural anaesthesia. This required extension of the blockade. Despite effective pain relief, extension proved difficult, and during the next hour, the patient received 9 ml of 0.37 5% and 13 ml of 0.5% bupivacaine plain through the catheter. Twenty minutes after the last injection, without any warning or symptoms, there was a sudden onset of a grand mal convulsion, lasting some 90s, accompanied by the rapid onset of deep cyanosis. Recovery was also rapid and complete, within a further 30 s. No cardiovascular abnormalities occurred and the arterial pressure remained unchanged. General anaesthesia was induced, and delivery undertaken. There were no untoward sequelae and the infant was delivered in good condition. The total dose of bupivacaine administered was 357.5mg over a 10-h period, and of that, 98.5mg was administered in the last 60 min.
Case 2
A primigravida aged 23 yr and weighing 54.9 kg, was admitted following the spontaneous onset of labour. Two hours after admission, extradural analgesia was instituted, using 0.375% bupivacaine plain solution. Pain relief was effective, and over the next 9h, the patient received bupivacaine 35 ml in divided doses. Twenty-five minutes after "topping up", 0.5% bupivacaine solution was injected to extend the block for Caesarean section. It proved rather difficult to achieve the required extent, and over a period of 70 min, 0.5% bupivacaine 45 ml was injected. The block was satisfactory although, following delivery (some 20 min following the last top up), the patient was noted to become drowsy. Suddenly she convulsed and transient cyanosis developed. Recovery followed rapidly, and diazepam was injected i.v. No sequelae ensued, the arterial pressure remained stable, and the subsequent course of the operation was uneventful.
A total dose of bupivacaine 356.25 mg plain solution had been administered over a 9-h period, 225 mg within the last 70 min.
DISCUSSION
The characteristics of the two patients were similar. Both had effective continuous extradural analgesia of similar duration. The presence of effective pain relief with standard "top-up" volumes, and the riming of the onset of convulsions which would coincide with the peak blood concentrations f ollow- With the increased popularity of extradural anaesthesia for Caesarean section, and the belief that it is perhaps safer than general anaesthesia, there is an understandable reluctance to undertake general anaesthesia in a patient whose extradural block is inadequate, but for whom the injection of further bupivacaine (which would exceed the manufacturer's recommended maximum dose) might create adequate blockade. This temptation should be resisted, the evidence presented here suggests that the total dose of bupivacaine injected should not be greater than that recommended by the manufacturer. It may be an advantage to use the more dilute solutions of bupivacaine to provide pain relief in labour, as this will decrease the total dose, and pain relief may still be adequate (Thorburn and Moir, 1981). The risks will then relate mainly to the use of larger volumes of more concentrated solutions for Caesarean section. 
